Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfamethylthiazole is a sulfonamide antibiotic, structurally related to other sulfonamides such as sulfamethoxazole and sulfamethizole. Like other drugs in this class, it acts as a bacteriostatic agent by inhibiting bacterial folic acid synthesis. Sulfamethylthiazole competitively inhibits the enzyme dihydropteroate synthase, blocking the conversion of para-aminobenzoic acid (PABA) to dihydrofolic acid, an essential precursor for nucleic acid and protein synthesis in bacteria. This mechanism disrupts DNA replication and cell division in susceptible organisms. Sulfonamide antibiotics are primarily used for treating various bacterial infections; however, specific indications for sulfamethylthiazole are less well documented compared to more commonly used agents like sulfamethoxazole[5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethylthiazole.